Bujalkova Maria, Zavodna Katarina, Krivulcik Tomas, Ilencikova Denisa, Wolf Brigitte, Kovac Michal, Karner-Hanusch Judith, Heinimann Karl, Marra Giancarlo, Jiricny Josef, Bartosova Zdena
Laboratory of Cancer Genetics, Cancer Research Institute of Slovak Academy of Sciences, Bratislava, Slovakia.
Clin Chem. 2008 Nov;54(11):1844-54. doi: 10.1373/clinchem.2008.108902. Epub 2008 Sep 4.
In the workup of patients with suspected hereditary nonpolyposis colorectal cancer (HNPCC), detection of loss of heterozygosity (LOH) could help pinpoint the mismatch-repair (MMR) gene carrying the germline mutation, but analysis of microsatellite markers has proved unreliable for this purpose. We developed a simple, low-cost method based on single-nucleotide polymorphism (SNP) genotyping and capillary electrophoresis for the assessment of LOH at 2 MMR loci simultaneously.
We used the Applied Biosystems SNaPshot Multiplex Kit with meticulously selected primers to assess 14 common SNPs in MLH1 [mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli)] and MSH2 [mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli)] and optimized the protocol for DNA isolated from peripheral blood and fresh/frozen or archival microsatellite-unstable tumors from patients with confirmed (n = 42) or suspected (n = 25) HNPCC. The 42 tumors from patients with confirmed MLH1 or MSH2 germline mutations were used to validate the method's diagnostic accuracy against results obtained with DNA sequencing or multiplex ligation-dependent probe amplification.
The SNaPshot assay provided better detection of certain SNPs than DNA sequencing. The MLH1 and MSH2 SNP marker sets were informative in 82% and 76% of the 67 cases analyzed, respectively. The new assay displayed 100% specificity for detecting LOH and predicted the location of the germline mutation in 40% of the cases (54% of those involving MLH1, 22% in MSH2).
Our SNP-based method for detecting LOH in MLH1 and MSH2 is simple to perform with instruments available in most clinical genetics laboratories. It can be a valuable addition to protocols now used to guide mutational screening of patients with suspected HNPCC.
在疑似遗传性非息肉病性结直肠癌(HNPCC)患者的检查中,检测杂合性缺失(LOH)有助于确定携带种系突变的错配修复(MMR)基因,但事实证明,为此目的分析微卫星标记并不可靠。我们开发了一种基于单核苷酸多态性(SNP)基因分型和毛细管电泳的简单、低成本方法,可同时评估2个MMR基因座处的LOH。
我们使用应用生物系统公司的SNaPshot多重试剂盒及精心挑选的引物,评估错配修复基因1(MLH1)[mutL同源物1,结肠癌,非息肉病2型(大肠杆菌)]和错配修复基因2(MSH2)[mutS同源物2,结肠癌,非息肉病1型(大肠杆菌)]中的14个常见SNP,并针对从确诊(n = 42)或疑似(n = 25)HNPCC患者的外周血以及新鲜/冷冻或存档的微卫星不稳定肿瘤中分离的DNA优化了实验方案。来自确诊携带MLH1或MSH2种系突变患者的42个肿瘤用于根据DNA测序或多重连接依赖探针扩增获得的结果验证该方法的诊断准确性。
SNaPshot分析对某些SNP的检测效果优于DNA测序。在分析的67例病例中,MLH1和MSH2 SNP标记集分别在82%和76%的病例中提供了有用信息。新方法在检测LOH方面显示出100%的特异性,并在40%的病例中预测了种系突变的位置(涉及MLH1的病例中为54%,MSH2中为22%)。
我们基于SNP检测MLH1和MSH2中LOH的方法使用大多数临床遗传学实验室都有的仪器即可简便操作。它可以成为目前用于指导疑似HNPCC患者突变筛查方案的有价值补充。